A Pilot Study To Evaluate the Effects of Lactobacillus Supplements

NCT ID: NCT05520073

Last Updated: 2023-03-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-09-01
• Study Completion Date: 2022-12-16

Brief Summary

This is a feasibility study to evaluate a decentralized (remote) clinical trial in Korea. In this study, an open-label, randomized, remote clinical trial to evaluate the effects of lactobacillus supplements on alleviating functional constipation symptoms in poor-health volunteers will be conducted.

Detailed Description

This study was designed for the purpose of confirming the feasibility of conducting a distributed clinical trial in the domestic medical environment and practically checking the considerations during implementation. This clinical trial aims to evaluate the effectiveness of interventions for functional constipation, a chronic disease, through the design of a fully distributed clinical trial, which is the most advanced form of distributed clinical trial. There are many patients with functional constipation around the world, and the need for a comparative randomized clinical trial for new treatments is being emphasized. It is expected to have a high potential for use in that it can be evaluated as In particular, health functional food preparations such as lactobacillus preparations have been reported to have effects on functional constipation, but it is difficult to prove their effectiveness due to the heterogeneity of clinical trial design5, so it can be considered as an application field for distributed clinical trials.

For this purpose, we intend to try an exploratory clinical trial to evaluate the effectiveness of lactic acid bacteria preparations in a distributed environment. In this clinical trial, patients are recruited remotely through a website, and visits to medical institutions are minimized by delivering lactic acid bacteria to home delivery and evaluating symptom improvement through self-recording symptoms. In addition, it is intended to ensure the accuracy of the collected data by having the urine vitamin C test be performed by oneself to check whether the drug is administered or not. Through this, it is expected that issues and considerations that may arise when designing distributed clinical trials in the future can be derived.

Conditions

Feasibility Studies

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: OTHER
• Blinding Strategy: NONE

Study Groups

Lactobacillus and Vitamin C

Lactobacillus and Vitamin C supplements daily self-administration for 14 days

Group Type: EXPERIMENTAL

Lactobacillus plantarum

Intervention Type: DIETARY_SUPPLEMENT

Lactobacillus product 1 pack daily

Vitamin C

Intervention Type: DIETARY_SUPPLEMENT

Vitamin C tablet 1 pack daily

Vitamin C

Vitamin C supplements daily self-administration for 14 days

Group Type: PLACEBO_COMPARATOR

Vitamin C

Intervention Type: DIETARY_SUPPLEMENT

Vitamin C tablet 1 pack daily

Interventions

Lactobacillus plantarum

Lactobacillus product 1 pack daily

Intervention Type: DIETARY_SUPPLEMENT

Vitamin C

Vitamin C tablet 1 pack daily

Intervention Type: DIETARY_SUPPLEMENT

Eligibility Criteria

Inclusion Criteria

• Adults aged between 19 and 64 years
• In the past 6 months, one or more of the following symptoms have been present for at least 2 weeks without having to be consecutive (based on alleviated Rome III functional constipation)

1. Excessive strain during defecation exceeds 1/4 of the total number of bowel movements

2. Lumpy or hard stool exceeds 1/4 of the total number of bowel movements

3. Feeling after defecation exceeds 1/4 of the total number of bowel movements

4. The feeling of anal obstruction during defecation exceeds 1/4 of the total number of bowel movements

5. More than 1/4 of the total number of bowel movements that require manual manipulation to help defecate

6. Less than 3 bowel movements per week

• A person who voluntarily decides to participate after hearing and fully understanding the detailed explanation of this clinical trial and consents before screening

Exclusion Criteria

• Those who have a clinically significant hypersensitivity reaction to lactic acid bacteria, vitamin C, or ingredients included in the drug
• Persons with a history or evidence of clinically significant blood, renal, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, liver, psychiatric, neurological or immune disease (eg, colorectal cancer, etc.)
• Those who are pregnant or lactating
• Those who cannot faithfully record self-recording of dosing and defecation within the clinical trial period
• Those who are taking or expected to take lactic acid bacteria or vitamin C preparations other than health functional foods to be administered in clinical trials within the period from 2 weeks before the scheduled first dose to the last dose
• Those who judged that the investigator is inappropriate to participate in the clinical trial due to other reasons

• Minimum Eligible Age: 19 Years
• Maximum Eligible Age: 64 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Seoul National University Hospital

OTHER

Sponsor Role: lead

Responsible Party

Kyung-Sang Yu

Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Kyung-Sang Yu, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Seoul National University Hospital

Locations

Seoul National University Hospital Clinical Trial Center

Seoul, , South Korea

Countries

South Korea

Other Identifiers

DCT-101

Identifier Type: -

Identifier Source: org_study_id